CClinicalTrials.gg
Active, not recruitingNCT02470260NOMEMUpdated May 7, 2025

Northern Manhattan Study of Metabolism and Mind

An observational study in Diabetes, Pre-diabetes and Cognition - Other, sponsored by Columbia University. Active, not recruiting at 1 site in United States. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-07.

Sponsored by Columbia University · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 3 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
50 Years to 64 Years
Sex
All
01

Study summary

Pre-diabetes, type 2 diabetes, and their related conditions, adiposity and insulin resistance, are more prevalent in minorities Northern Manhattan compared to the general population of the United States. Despite knowledge of the main biologic determinants of these conditions (high caloric intake and sedentarism) the prevalence of these conditions continue to increase. In addition, these conditions can cause mental health problems including increased depressive symptoms and cognitive impairment. Thus, the investigators decided to conduct a community based study of middle aged Hispanic men and women aged 50 to 64 years at baseline in order to:

  1. Document the prevalence and incidence, of pre-diabetes, diabetes, overweight, obesity, and associated conditions (e.g. dyslipidemia, hypertension).
  2. Study how social determinants of health (SDOH) affect these conditions.
  3. Study the consequences of these conditions on aging and mental health outcomes, including cognitive impairment.
Read the detailed description

DESIGN OVERVIEW: the Northern Manhattan Study of Metabolism and Mind (NOMEM) is a longitudinal cohort study of middle aged Hispanics. Recruitment of the initial cohort of 600 participants was completed between January of 2012 and December of 2013. Our total target sample size is 1000 participants. Participants are followed every 2 years. Participants are self-identified Hispanic men and women aged 50 to 65 years. The sampling frame is the community of Northern Manhattan in New York City.

Participants undergo phlebotomy, measurement of vital signs and anthropometric measures, interviews of medical history, cognitive assessments, and interviews of social determinants of health and mental and physical conditions. Assessments take between 2 and 3 hours.

VARIABLES:

  • Glycemia and diabetes status: glycemia is measured with HbA1c. Diabetes is defined by clinical history or by HbA1c ≥ 6.5%, following 2010 ADA criteria. Pre-diabetes is determined following ADA 2010 criteria (HbA1c 5.7 to 6.4%).
  • APOE genotyping: The 3 APOE alleles will be genotyped, ε2, ε3, and ε4.
  • Body Mass Index (BMI). Standing height is measured using a stadiometer calibrated in cm. Body weight is measured using a balance beam scale calibrated in kg. With the participant standing, measurements are taken to the nearest 0.1 kg of weight with a balance scale and height without shoes to nearest 0.5 cm, to calculate BMI (weight/height2). (use: covariate, ancillary studies).
  • Demographic variables: We collect date of birth, sex, years and education, racial group, and country of origin (following the 2010 census format for Hispanics) (use: covariates).
  • Depression: We measure depression and depressive symptoms using the PHQ9 and the PROMIS depression scale.
  • High sensitivity CRP: Measured using ELISA (Diagnostic systems laboratories, INC, Webster, Texas). The assay sensitivity is 1.6 ng/ml, the inter-assay CV is 11.7%, and the intra-assay CV is 4.6%. This assay can be conducted in serum or plasma.
  • Lipids: total cholesterol (TC), HDL. TC and HDL are measured using enzymatic colorimetric methods (Vitros; Johnson \& Johnson, New Brunswick, NJ).
  • Medical history.This includes vascular disease, cancer, and smoking
  • Medications: We will record medications, vitamins, and over the counter products (use: covariate, ancillary studies).
  • Resting blood pressure (BP): BP will be measured using an automated oscillometric device; 3 measurements are obtained at 1-minute intervals in a seated position after 5 minutes of rest. The average of the 2nd and 3rd measurements will be recorded as the BP.
  • Waist and hip circumference: Waist circumference is measured at the level of the umbilicus. Hip circumference is measured at the level of maximal protrusion of the gluteal muscles. Waist-hip ratio is calculated as the ratio of waist circumference to hip circumference.
  • Cognitive battery:

    • WAIS-R Similarities. This Wechsler Adult Intelligence Scale-Revised subtest has good norms and is a standard portion of a dementia evaluation. The items have been translated into Spanish and a scoring guide has been developed. Age-Scaled scores will be used. [Max. Score=19; Time=5 min] Non-Verbal Similarities. The Identities and Oddities subtest of the Mattis Dementia Rating Scale is used to assess nonverbal abstract reasoning. [Max. Score=16; Time=2 min]
    • Color Trails Test Color Trails 1 is a test of sustained visual attention, psychomotor speed, and simple sequencing and involves connecting circles containing the numbers 1 through 25 in order as quickly as possible. Color Trails 2 also involves connecting circles containing the numbers 1 through 25 in order as quickly as possible, but the examinee must shift between pink and yellow colored circles. Like Part 1, Color Trails 2 assesses visual attention and psychomotor speed but also requires a higher level of executive functioning skills.
    • Verbal Fluency: Controlled Word Association Test. The patient is given 1 min to name as many words beginning with a particular letter as s/he can. Norms and frequency counts exist for this test in Spanish as well as English. Three categories, Animals, Food, and Clothing are administered to assess category naming. [Time=7 min]
    • The Selective Reminding Test (SRT) is a standard tool in the assessment of verbal memory and dementia and has been used as a sensitive longitudinal measure of changes in memory function. The SRTwas translated into Spanish using words of similar frequency to those in the standard test versions. Subjects are given 6 trials to learn a list of 12 unrelated words. After each attempt at recalling the list, the subject is reminded only of the words that were not recalled and then must attempt to recall the entire list. To assess short-term memory, 2 measures are used: total recall (max. score=72) and retrieval from long-term storage (max. score=72). To assess long-term recall, delayed recall is assessed 15 minutes after completing the SRT (max. score=12); recognition of words not recalled is then tested using multiple choice arrays (max. score=12). [Time (not including 15 min. delay interval, during which other tests are administered) =15 min].
    • The orientation items from the modified Mini-Mental State Examination are used to assess orientation to time and place. These items are sensitive to dementing changes in our normative samples. [Max. Score=10; Time to administer=2 min]
  • Social Determinants of Health:

    • Individual SES: MacArthur Network on SES and Health Measures Household income/number of people supported, wealth, debt, how long one could live at current lifestyle if current sources of income ceased
    • Perceived Social Status: MacArthur Ladder; Perceived relative standing in the US
    • Migration: Age at migration Years of life in US
    • Everyday Discrimination* Everyday Discrimination; 10 items; Daily discriminatory hassles
    • Major Discrimination* Modified Experiences of Discrimination Scale:

      12 items; Frequency measure of total lifetime occurrences; 0=Never to 5=Four or More Times

    • Coping with Discrimination-Psychosocial Experiences of Discrimination Scale; 3 coping styles-0=Passive (accept/quiet); 1=Moderate (quiet); 2=Engaged (do something/talk to others)
    • Coping with Discrimination-Health Behavior Modified Experiences of Discrimination Scale 4 behaviors-Exercising, eating sweets/fatty foods, drinking alcohol, smoking cigarettes 0=Never; 3=most of the time
    • Coping with Stress-Psychosocial Based on Experiences of Discrimination Scale 3 coping styles-0=Passive (accept/quiet); 1=Moderate (quiet); 2=Engaged (do something/talk to others)
    • Coping with Stress-Health Behavior Modified Experiences of Discrimination Scale 4 behaviors-Exercising, eating sweets/fatty foods, drinking alcohol, smoking cigarettes; 0=Never; 3=most of the time
    • Racial/Ethnic Socialization Racial/Ethnic Socialization Scale 15 items; 0=Never, 1=Almost Never; 2=Sometimes; 3=Often; 4=Very Often
    • Ethnic Identity Multi-Ethnic Identity Measure 12 items from Affirmation and Belonging and Ethnic Identity Search subscales
    • Acculturation Bidimensional Acculturation Scale Average of 12 items in each domain (Hispanic, Non-Hispanic)
    • Alcohol Use Alcohol Use Disorders Identification Test 10 items; Items scored 0-4
    • Smoking From COHD battery Cigarettes smoked daily
    • Diet Behavioral Risk Factor Surveillance System 6 items; 1=More than Once a Day; 5=Less than Once a Week
    • Physical Activity IPAQ Summation of the duration (in minutes) and frequency (days) of walking, moderate-intensity and vigorous-intensity activities to estimate MET minutes/week
    • Barriers to Exercise* Benefits and Barriers to Exercise71 9 items; 0=Never; 5=Very Often
    • John Henryism John Henryism Active Coping Scale 12 items; 1=Completely True; 5=Completely False
    • Social Support Social Support Questionnaire Count # of people for odd items. Add totals (Max=54). Divide by 6 for per item SSQ Number Score. Add total Satisfaction score for 6 even numbered items
    • Neighborhood Resources Census-derived neighborhood deprivation % living or below poverty line
02

Conditions studied

  • Diabetes
  • Pre-diabetes
  • Cognition - Other
  • Depressive Symptoms
  • Metabolic Syndrome

Keywords

  • Diabetes
  • Pre-diabetes
  • Cognition
  • Depressive symptoms
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Columbia University is the lead sponsor of 1,103 studies on the registry; 193 are open to participants now.

Of its 172 completed or terminated interventional studies of FDA-regulated products, 142 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Middle aged Hispanics from Northern Manhattan, New York City

Inclusion criteria

  • Self identified Hispanic (any Hispanic subgroup)
  • Man or woman.
  • Between the ages of 50 and 64 years at baseline

Exclusion criteria

Exclusion Criteria:

  • History of cancer other than non-melanoma skin cancer

    • The expectation of moving out for the country permanently before during the study period
    • Presence of a clinical diagnosis of dementia, which we anticipate will be unlikely in this age group.
    • Visual, hearing, or physical impairment that precludes active participation in the study and inability to complete study questionnaires.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Diabetes

    Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)

  • Pre-diabetes

    Defined by HbA1c criteria (5.7 to 6.4%)

  • Normal glucose tolerance

    Defined by HbA1c criteria (\< 5.7%)

06

What researchers measure

Primary outcomes

  1. Cognition

    cognitive change over at least 3 follow-ups measured with the Selective Reminding Test, Color trails test, and Animal fluency tests.

    Time frame: 6 years

Secondary outcomes

  1. Transitions in diabetes status

    Transition from a diabetes state (normal glucose tolerance, pre-diabetes, diabetes) to another state (normal glucose tolerance, pre-diabetes,diabetes). HbA1 is used to ascertain Normal glucose tolerance (HbA1c \< 6.7%) and pre-diabetes (HbA1c between 6.7 and 6.49%).

    Time frame: 6 years

  2. Metabolic syndrome

    The components of the metabolic syndrome are:hyperglycemia (pre diabetes or diabetes), central obesity (determined with waist circumference, low HDL, hypertension, and inflammation (hsCRP \> 3); the metabolic syndrome is present when 3 or more of the components are present.

    Time frame: 6 years

  3. Depressive symptoms

    assessed with the PHQ9 and the PROMIS depression scale

    Time frame: 6 years

07

Study locations

1 site
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02470260
Lead sponsor
Columbia University
Collaborators
National Institute on Minority Health and Health Disparities (NIMHD), National Institute on Aging (NIA)
Responsible party
José A. Luchsinger (Professor of Medicine and Epidemiology, Columbia University) — Principal investigator
First posted
Jun 12, 2015
Start date
Jan 2012
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
May 7, 2025

Study contacts

Jose A. Luchsinger, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion